The IL–10/STAT3 axis: Contributions to immune tolerance by thymus and peripherally derived regulatory T-cells

European Journal of Immunology

Volumn 47, Issue 8, 2017, Pages 1256-1265

  Schmetterer, Klaus G ^a   Pickl, Winfried F ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

IL 10; Regulatory T cells; STAT3; Tolerance; Tr1 cells

Indexed keywords

INTERLEUKIN 10; STAT3 PROTEIN; CYTOKINE; INTERLEUKIN 6;

HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOGENESIS; NONHUMAN; PERIPHERAL LYMPHOCYTE; PERIPHERALLY DERIVED REGULATORY T LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; REVIEW; THYMUS; ANIMAL; AUTOIMMUNE DISEASE; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CYTOLOGY; GENE EXPRESSION REGULATION; HYPER IGE SYNDROME; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASE; METABOLISM; MOUSE; SIGNAL TRANSDUCTION;

ANIMALS; AUTOIMMUNE DISEASES; CD4-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CYTOKINES; GENE EXPRESSION REGULATION; HUMANS; IMMUNE TOLERANCE; INFLAMMATORY BOWEL DISEASES; INTERLEUKIN-10; INTERLEUKIN-6; JOB SYNDROME; MICE; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; T-LYMPHOCYTES, REGULATORY; THYMUS GLAND;

EID: 85025076958     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201646710     Document Type: Review

References (94)

1. Klein, J., Immunology The Science of Self–Nonself Discrimination, John Wiley & Sons, New York, 1982.
2. Abbas, A. K., Benoist, C., Bluestone, J. A., Campbell, D. J., Ghosh, S., Hori, S., Jiang, S. et al., Regulatory T-cells: recommendations to simplify the nomenclature. Nat. Immunol. 2013. 14: 307–308.
3. Shevach, E. M., From vanilla to 28 flavors: multiple varieties of T regulatory cells. Immunity 2006. 25: 195–201.
4. Fontenot, J. D., Gavin, M. A. and Rudensky, A. Y., Foxp3 programs the development and function of CD4+CD25+ regulatory T-cells. Nat. Immunol. 2003. 4: 330–336.
5. Hori, S., Nomura, T. and Sakaguchi, S., Control of regulatory T-cell development by the transcription factor Foxp3. Science 2003. 299: 1057–1061.
6. Schmetterer, K. G., Haiderer, D., Leb–Reichl, V. M., Neunkirchner, A., Jahn–Schmid, B., Kung, H. J., Schuch, K. et al., Bet v 1–specific T-cell receptor/forkhead box protein 3 transgenic T-cells suppress Bet v 1–specific T-cell effector function in an activation–dependent manner. J. Allergy. Clin. Immunol. 2011. 127: 238–245, 245 e231–233.
7. Schmetterer, K. G., Neunkirchner, A., Wojta–Stremayr, D., Leitner, J., Steinberger, P. and Pickl, W. F., STAT3 governs hyporesponsiveness and granzyme B–dependent suppressive capacity in human CD4+ T-cells. FASEB J. 2015. 29: 759–771.
8. Roncarolo, M. G., Gregori, S., Bacchetta, R. and Battaglia, M., Tr1 cells and the counter–regulation of immunity: natural mechanisms and therapeutic applications. Curr. Top. Microbiol. Immunol. 2014. 380: 39–68.
9. Vieira, P., de Waal–Malefyt, R., Dang, M. N., Johnson, K. E., Kastelein, R., Fiorentino, D. F., deVries, J. E. et al., Isolation and expression of human cytokine synthesis inhibitory factor cDNA clones: homology to Epstein–Barr virus open reading frame BCRFI. Proc. Natl. Acad. Sci. USA 1991. 88: 1172–1176.
10. de Saint–Vis, B., Fugier–Vivier, I., Massacrier, C., Gaillard, C., Vanbervliet, B., Ait–Yahia, S., Banchereau, J. et al., The cytokine profile expressed by human dendritic cells is dependent on cell subtype and mode of activation. J. Immunol. 1998. 160: 1666–1676.
11. van der Poll, T., Jansen, J., Levi, M., ten Cate, H., ten Cate, J. W. and van Deventer, S. J., Regulation of interleukin 10 release by tumor necrosis factor in humans and chimpanzees. J. Exp. Med. 1994. 180: 1985–1988.
12. Wanidworanun, C. and Strober, W., Predominant role of tumor necrosis factor–alpha in human monocyte IL–10 synthesis. J. Immunol. 1993. 151: 6853–6861.
13. Cua, D. J., Groux, H., Hinton, D. R., Stohlman, S. A. and Coffman, R. L., Transgenic interleukin 10 prevents induction of experimental autoimmune encephalomyelitis. J. Exp. Med. 1999. 189: 1005–1010.
14. Josephson, K., Logsdon, N. J. and Walter, M. R., Crystal structure of the IL–10/IL–10R1 complex reveals a shared receptor binding site. Immunity 2001. 15: 35–46.
15. Goswami, R. and Kaplan, M. H., STAT transcription factors in T-cell control of health and disease. Int Rev Cell Mol Biol 2017. 331: 123–180.
16. Levy, D. E. and Darnell, J. E., Jr., Stats: transcriptional control and biological impact. Nat. Rev. Mol. Cell Biol. 2002. 3: 651–662.
17. Villarino, A. V., Kanno, Y. and O'Shea, J. J., Mechanisms and consequences of Jak–STAT signaling in the immune system. Nat. Immunol. 2017. 18: 374–384.
18. Yang, X. P., Ghoreschi, K., Steward–Tharp, S. M., Rodriguez–Canales, J., Zhu, J., Grainger, J. R., Hirahara, K. et al., Opposing regulation of the locus encoding IL–17 through direct, reciprocal actions of STAT3 and STAT5. Nat. Immunol. 2011. 12: 247–254.
19. Tibbitt, C., Falconer, J., Stoop, J., van Eden, W., Robinson, J. H. and Hilkens, C. M., Reduced TCR–dependent activation through citrullination of a T-cell epitope enhances Th17 development by disruption of the STAT3/5 balance. Eur. J. Immunol. 2016. 46: 1633–1643.
20. Zheng, J., van de Veerdonk, F. L., Crossland, K. L., Smeekens, S. P., Chan, C. M., Al Shehri, T., Abinun, M. et al., Gain–of–function STAT1 mutations impair STAT3 activity in patients with chronic mucocutaneous candidiasis (CMC). Eur. J. Immunol. 2015. 45: 2834–2846.
21. Minegishi, Y., Saito, M., Tsuchiya, S., Tsuge, I., Takada, H., Hara, T., Kawamura, N., Ariga, T. et al., Dominant–negative mutations in the DNA–binding domain of STAT3 cause hyper–IgE syndrome. Nature 2007. 448: 1058–1062.
22. Davis, S. D., Schaller, J. and Wedgwood, R. J., Job's syndrome. Recurrent, "cold", staphylococcal abscesses. Lancet 1966. 1: 1013–1015.
23. Glocker, E. O., Kotlarz, D., Boztug, K., Gertz, E. M., Schaffer, A. A., Noyan, F., Perro, M. et al., Inflammatory bowel disease and mutations affecting the interleukin–10 receptor. N. Engl. J. Med. 2009. 361: 2033–2045.
24. Kuhn, R., Lohler, J., Rennick, D., Rajewsky, K. and Muller, W., Interleukin–10–deficient mice develop chronic enterocolitis. Cell 1993. 75: 263–274.
25. MacDonald, T. T., Gastrointestinal inflammation. Inflammatory bowel disease in knockout mice. Curr. Biol. 1994. 4: 261–263.
26. Kotlarz, D., Beier, R., Murugan, D., Diestelhorst, J., Jensen, O., Boztug, K., Pfeifer, D. et al., Loss of interleukin–10 signaling and infantile inflammatory bowel disease: implications for diagnosis and therapy. Gastroenterology 2012. 143: 347–355.
27. Ma, C. S., Avery, D. T., Chan, A., Batten, M., Bustamante, J., Boisson–Dupuis, S., Arkwright, P. D. et al., Functional STAT3 deficiency compromises the generation of human T follicular helper cells. Blood 2012. 119: 3997–4008.
28. McIlwain, D. R., Grusdat, M., Pozdeev, V. I., Xu, H. C., Shinde, P., Reardon, C., Hao, Z. et al., T-cell STAT3 is required for the maintenance of humoral immunity to LCMV. Eur. J. Immunol. 2015. 45: 418–427.
29. Bacchetta, R., Bigler, M., Touraine, J. L., Parkman, R., Tovo, P. A., Abrams, J., de Waal Malefyt, R. et al., High levels of interleukin 10 production in vivo are associated with tolerance in SCID patients transplanted with HLA mismatched hematopoietic stem cells. J. Exp. Med. 1994. 179: 493–502.
30. Magnani, C. F., Alberigo, G., Bacchetta, R., Serafini, G., Andreani, M., Roncarolo, M. G. and Gregori, S., Killing of myeloid APCs via HLA class I, CD2 and CD226 defines a novel mechanism of suppression by human Tr1 cells. Eur. J. Immunol. 2011. 41: 1652–1662.
31. Gregori, S., Goudy, K. S. and Roncarolo, M. G., The cellular and molecular mechanisms of immuno–suppression by human type 1 regulatory T-cells. Front Immunol 2012. 3: 30.
32. Bacchetta, R., Sartirana, C., Levings, M. K., Bordignon, C., Narula, S. and Roncarolo, M. G., Growth and expansion of human T regulatory type 1 cells are independent from TCR activation but require exogenous cytokines. Eur. J. Immunol. 2002. 32: 2237–2245.
33. Groux, H., O'Garra, A., Bigler, M., Rouleau, M., Antonenko, S., de Vries, J. E. and Roncarolo, M. G., A CD4+ T-cell subset inhibits antigen–specific T-cell responses and prevents colitis. Nature 1997. 389: 737–742.
34. Gagliani, N., Magnani, C. F., Huber, S., Gianolini, M. E., Pala, M., Licona–Limon, P., Guo, B. et al., Coexpression of CD49b and LAG–3 identifies human and mouse T regulatory type 1 cells. Nat. Med. 2013. 19: 739–746.
35. White, A. M. and Wraith, D. C., Tr1–like T-cells – an enigmatic regulatory T-cell lineage. Front. Immunol. 2016. 7: 355.
36. Gagliani, N., Amezcua Vesely, M. C., Iseppon, A., Brockmann, L., Xu, H., Palm, N. W., de Zoete, M. R. et al., Th17 cells transdifferentiate into regulatory T-cells during resolution of inflammation. Nature 2015. 523: 221–225.
37. Mascanfroni, I. D., Takenaka, M. C., Yeste, A., Patel, B., Wu, Y., Kenison, J. E., Siddiqui, S. et al., Metabolic control of type 1 regulatory T-cell differentiation by AHR and HIF1–alpha. Nat. Med. 2015. 21: 638–646.
38. Newton, R., Priyadharshini, B. and Turka, L. A., Immunometabolism of regulatory T-cells. Nat. Immunol. 2016. 17: 618–625.
39. Stumhofer, J. S., Silver, J. S., Laurence, A., Porrett, P. M., Harris, T. H., Turka, L. A., Ernst, M. et al., Interleukins 27 and 6 induce STAT3–mediated T-cell production of interleukin 10. Nat. Immunol. 2007. 8: 1363–1371.
40. Andolfi, G., Fousteri, G., Rossetti, M., Magnani, C. F., Jofra, T., Locafaro, G., Bondanza, A. et al., Enforced IL–10 expression confers type 1 regulatory T-cell (Tr1) phenotype and function to human CD4(+) T-cells. Mol. Ther. 2012. 20: 1778–1790.
41. Levings, M. K., Sangregorio, R., Galbiati, F., Squadrone, S., de Waal Malefyt, R. and Roncarolo, M. G., IFN–alpha and IL–10 induce the differentiation of human type 1 T regulatory cells. J. Immunol. 2001. 166: 5530–5539.
42. Ziegler–Heitbrock, L., Lotzerich, M., Schaefer, A., Werner, T., Frankenberger, M. and Benkhart, E., IFN–alpha induces the human IL–10 gene by recruiting both IFN regulatory factor 1 and Stat3. J. Immunol. 2003. 171: 285–290.
43. Gregori, S., Passerini, L. and Roncarolo, M. G., Clinical outlook for Type–1 and FOXP3(+) T regulatory cell–based therapy. Front Immunol 2015. 6: 593.
44. Zohar, Y., Wildbaum, G., Novak, R., Salzman, A. L., Thelen, M., Alon, R., Barsheshet, Y. et al., CXCL11–dependent induction of FOXP3–negative regulatory T-cells suppresses autoimmune encephalomyelitis. J. Clin. Invest. 2014. 124: 2009–2022.
45. Meiron, M., Zohar, Y., Anunu, R., Wildbaum, G. and Karin, N., CXCL12 (SDF–1alpha) suppresses ongoing experimental autoimmune encephalomyelitis by selecting antigen–specific regulatory T-cells. J. Exp. Med. 2008. 205: 2643–2655.
46. Shaim, H., Estrov, Z., Sekine, T., Kondo, K., Ruvolo, P. P., Thompson, P., Sarvaria, A. et al., The CXCR4/STAT3/IL–10 pathway controls the immunoregulatory function of chronic lymphocytic leukemia (CLL) and can be modulated by lenalidomide. Blood 2015. 126: 1709.
47. Brockmann, L., Gagliani, N., Steglich, B., Giannou, A. D., Kempski, J., Pelczar, P., Geffken, M. et al., IL–10 receptor signaling is essential for TR1 cell function in vivo. J. Immunol. 2017. 198: 1130–1141.
48. Pflanz, S., Timans, J. C., Cheung, J., Rosales, R., Kanzler, H., Gilbert, J., Hibbert, L. et al., IL–27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4+ T-cells. Immunity 2002. 16: 779–790.
49. Gazzinelli, R. T., Wysocka, M., Hieny, S., Scharton–Kersten, T., Cheever, A., Kuhn, R., Muller, W. et al., In the absence of endogenous IL–10, mice acutely infected with Toxoplasma gondii succumb to a lethal immune response dependent on CD4+ T-cells and accompanied by overproduction of IL–12, IFN–gamma and TNF–alpha. J. Immunol. 1996. 157: 798–805.
50. Villarino, A., Hibbert, L., Lieberman, L., Wilson, E., Mak, T., Yoshida, H., Kastelein, R. A. et al., The IL–27R (WSX–1) is required to suppress T-cell hyperactivity during infection. Immunity 2003. 19: 645–655.
51. Awasthi, A., Carrier, Y., Peron, J. P., Bettelli, E., Kamanaka, M., Flavell, R. A., Kuchroo, V. K. et al., A dominant function for interleukin 27 in generating interleukin 10–producing anti–inflammatory T-cells. Nat. Immunol. 2007. 8: 1380–1389.
52. Fitzgerald, D. C., Zhang, G. X., El–Behi, M., Fonseca–Kelly, Z., Li, H., Yu, S., Saris, C. J. et al., Suppression of autoimmune inflammation of the central nervous system by interleukin 10 secreted by interleukin 27–stimulated T-cells. Nat. Immunol. 2007. 8: 1372–1379.
53. Wang, H., Meng, R., Li, Z., Yang, B., Liu, Y., Huang, F., Zhang, J. et al., IL–27 induces the differentiation of Tr1–like cells from human naive CD4+ T-cells via the phosphorylation of STAT1 and STAT3. Immunol. Lett. 2011. 136: 21–28.
54. Iwasaki, Y., Fujio, K., Okamura, T., Yanai, A., Sumitomo, S., Shoda, H., Tamura, T. et al., Egr–2 transcription factor is required for Blimp–1–mediated IL–10 production in IL–27–stimulated CD4+ T-cells. Eur. J. Immunol. 2013. 43: 1063–1073.
55. Apetoh, L., Quintana, F. J., Pot, C., Joller, N., Xiao, S., Kumar, D., Burns, E. J. et al., The aryl hydrocarbon receptor interacts with c–Maf to promote the differentiation of type 1 regulatory T-cells induced by IL–27. Nat. Immunol. 2010. 11: 854–861.
56. Borsellino, G., Kleinewietfeld, M., Di Mitri, D., Sternjak, A., Diamantini, A., Giometto, R., Hopner, S. et al., Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 2007. 110: 1225–1232.
57. Deaglio, S., Dwyer, K. M., Gao, W., Friedman, D., Usheva, A., Erat, A., Chen, J. F. et al., Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T-cells mediates immune suppression. J. Exp. Med. 2007. 204: 1257–1265.
58. Widerak, M., Ghoneim, C., Dumontier, M. F., Quesne, M., Corvol, M. T. and Savouret, J. F., The aryl hydrocarbon receptor activates the retinoic acid receptoralpha through SMRT antagonism. Biochimie 2006. 88: 387–397.
59. Flores, R. R., Kim, E., Zhou, L., Yang, C., Zhao, J., Gambotto, A. and Robbins, P. D., IL–Y, a synthetic member of the IL–12 cytokine family, suppresses the development of type 1 diabetes in NOD mice. Eur. J. Immunol. 2015. 45: 3114–3125.
60. Wang, R. X., Yu, C. R., Mahdi, R. M. and Egwuagu, C. E., Novel IL27p28/IL12p40 cytokine suppressed experimental autoimmune uveitis by inhibiting autoreactive Th1/Th17 cells and promoting expansion of regulatory T-cells. J. Biol. Chem. 2012. 287: 36012–36021.
61. Johansson, A. C., Hansson, A. S., Nandakumar, K. S., Backlund, J. and Holmdahl, R., IL–10–deficient B10.Q mice develop more severe collagen–induced arthritis, but are protected from arthritis induced with anti–type II collagen antibodies. J. Immunol. 2001. 167: 3505–3512.
62. Akdis, C. A. and Blaser, K., IL–10–induced anergy in peripheral T-cell and reactivation by microenvironmental cytokines: two key steps in specific immunotherapy. FASEB J. 1999. 13: 603–609.
63. Bettelli, E., Das, M. P., Howard, E. D., Weiner, H. L., Sobel, R. A. and Kuchroo, V. K., IL–10 is critical in the regulation of autoimmune encephalomyelitis as demonstrated by studies of IL–10– and IL–4–deficient and transgenic mice. J. Immunol. 1998. 161: 3299–3306.
64. Burton, B. R., Britton, G. J., Fang, H., Verhagen, J., Smithers, B., Sabatos–Peyton, C. A., Carney, L. J. et al., Sequential transcriptional changes dictate safe and effective antigen–specific immunotherapy. Nat Commun 2014. 5: 4741.
65. Gabrysova, L. and Wraith, D. C., Antigenic strength controls the generation of antigen–specific IL–10–secreting T regulatory cells. Eur. J. Immunol. 2010. 40: 1386–1395.
66. Nicolson, K. S., O'Neill, E. J., Sundstedt, A., Streeter, H. B., Minaee, S. and Wraith, D. C., Antigen–induced IL–10+ regulatory T-cells are independent of CD25+ regulatory cells for their growth, differentiation, and function. J. Immunol. 2006. 176: 5329–5337.
67. Verhagen, J., Gabrysova, L., Shepard, E. R. and Wraith, D. C., Ctla–4 modulates the differentiation of inducible Foxp3+ Treg cells but IL–10 mediates their function in experimental autoimmune encephalomyelitis. PLoS One 2014. 9: e108023.
68. Martinez–Forero, I., Garcia–Munoz, R., Martinez–Pasamar, S., Inoges, S., Lopez–Diaz de Cerio, A., Palacios, R., Sepulcre, J. et al., IL–10 suppressor activity and ex vivo Tr1 cell function are impaired in multiple sclerosis. Eur. J. Immunol. 2008. 38: 576–586.
69. Colombel, J. F., Rutgeerts, P., Malchow, H., Jacyna, M., Nielsen, O. H., Rask–Madsen, J., Van Deventer, S. et al., Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease. Gut 2001. 49: 42–46.
70. Fedorak, R. N., Gangl, A., Elson, C. O., Rutgeerts, P., Schreiber, S., Wild, G., Hanauer, S. B. et al., Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology 2000. 119: 1473–1482.
71. Kelsall, B., Interleukin–10 in inflammatory bowel disease. N. Engl. J. Med. 2009. 361: 2091–2093.
72. Schreiber, S., Fedorak, R. N., Nielsen, O. H., Wild, G., Williams, C. N., Nikolaus, S., Jacyna, M. et al., Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL–10 Cooperative Study Group. Gastroenterology 2000. 119: 1461–1472.
73. Nagamine, K., Peterson, P., Scott, H. S., Kudoh, J., Minoshima, S., Heino, M., Krohn, K. J. et al., Positional cloning of the APECED gene. Nat. Genet. 1997. 17: 393–398.
74. Khattri, R., Cox, T., Yasayko, S. A. and Ramsdell, F., An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat. Immunol. 2003. 4: 337–342.
75. Chatila, T. A., Blaeser, F., Ho, N., Lederman, H. M., Voulgaropoulos, C., Helms, C. and Bowcock, A. M., JM2, encoding a fork head–related protein, is mutated in X–linked autoimmunity–allergic disregulation syndrome. J. Clin. Invest. 2000. 106: R75–R81.
76. Bacchetta, R., Barzaghi, F. and Roncarolo, M. G., From IPEX syndrome to FOXP3 mutation: a lesson on immune dysregulation. Ann. N. Y. Acad. Sci. 2016. https://doi.org/10.1111/nyas.13011
77. Schmetterer, K. G., Neunkirchner, A. and Pickl, W. F., Naturally occurring regulatory T-cells: markers, mechanisms, and manipulation. FASEB J. 2012. 26: 2253–2276.
78. Chaudhry, A., Rudra, D., Treuting, P., Samstein, R. M., Liang, Y., Kas, A. and Rudensky, A. Y., CD4+ regulatory T-cells control TH17 responses in a Stat3–dependent manner. Science 2009. 326: 986–991.
79. Hirahara, K., Ghoreschi, K., Laurence, A., Yang, X. P., Kanno, Y. and O'Shea, J. J., Signal transduction pathways and transcriptional regulation in Th17 cell differentiation. Cytokine Growth Factor Rev. 2010. 21: 425–434.
80. Koch, M. A., Tucker–Heard, G., Perdue, N. R., Killebrew, J. R., Urdahl, K. B. and Campbell, D. J., The transcription factor T–bet controls regulatory T-cell homeostasis and function during type 1 inflammation. Nat. Immunol. 2009. 10: 595–602.
81. Zheng, Y., Chaudhry, A., Kas, A., deRoos, P., Kim, J. M., Chu, T. T., Corcoran, L. et al., Regulatory T-cell suppressor program co–opts transcription factor IRF4 to control T(H)2 responses. Nature 2009. 458: 351–356.
82. Chaudhry, A., Samstein, R. M., Treuting, P., Liang, Y., Pils, M. C., Heinrich, J. M., Jack, R. S. et al., Interleukin–10 signaling in regulatory T-cells is required for suppression of Th17 cell–mediated inflammation. Immunity 2011. 34: 566–578.
83. Kluger, M. A., Luig, M., Wegscheid, C., Goerke, B., Paust, H. J., Brix, S. R., Yan, I. et al., Stat3 programs Th17–specific regulatory T-cells to control GN. J. Am. Soc. Nephrol. 2014. 25: 1291–1302.
84. Kluger, M. A., Melderis, S., Nosko, A., Goerke, B., Luig, M., Meyer, M. C., Turner, J. E. et al., Treg17 cells are programmed by Stat3 to suppress Th17 responses in systemic lupus. Kidney Int. 2016. 89: 158–166.
85. Gautron, A. S., Dominguez–Villar, M., de Marcken, M. and Hafler, D. A., Enhanced suppressor function of TIM–3+ FoxP3+ regulatory T-cells. Eur. J. Immunol. 2014. 44: 2703–2711.
86. Hossain, D. M., Panda, A. K., Manna, A., Mohanty, S., Bhattacharjee, P., Bhattacharyya, S., Saha, T. et al., FoxP3 acts as a cotranscription factor with STAT3 in tumor–induced regulatory T-cells. Immunity 2013. 39: 1057–1069.
87. Pallandre, J. R., Brillard, E., Crehange, G., Radlovic, A., Remy–Martin, J. P., Saas, P., Rohrlich, P. S. et al., Role of STAT3 in CD4+CD25+FOXP3+ regulatory lymphocyte generation: implications in graft–versus–host disease and antitumor immunity. J. Immunol. 2007. 179: 7593–7604.
88. Liu, X., Nurieva, R. I. and Dong, C., Transcriptional regulation of follicular T–helper (Tfh) cells. Immunol. Rev. 2013. 252: 139–145.
89. Zhou, L., Ivanov, II, Spolski, R., Min, R., Shenderov, K., Egawa, T., Levy, D. E. et al., IL–6 programs T(H)–17 cell differentiation by promoting sequential engagement of the IL–21 and IL–23 pathways. Nat. Immunol. 2007. 8: 967–974.
90. Oh, H. M., Yu, C. R., Dambuza, I., Marrero, B. and Egwuagu, C. E., STAT3 protein interacts with Class O Forkhead transcription factors in the cytoplasm and regulates nuclear/cytoplasmic localization of FoxO1 and FoxO3a proteins in CD4(+) T-cells. J. Biol. Chem. 2012. 287: 30436–30443.
91. Flanagan, S. E., Haapaniemi, E., Russell, M. A., Caswell, R., Lango Allen, H., De Franco, E., McDonald, T. J. et al., Activating germline mutations in STAT3 cause early–onset multi–organ autoimmune disease. Nat. Genet. 2014. 46: 812–814.
92. Milner, J. D., Vogel, T. P., Forbes, L., Ma, C. A., Stray–Pedersen, A., Niemela, J. E., Lyons, J. J. et al., Early–onset lymphoproliferation and autoimmunity caused by germline STAT3 gain–of–function mutations. Blood 2015. 125: 591–599.
93. Delgoffe, G. M. and Vignali, D. A., STAT heterodimers in immunity: a mixed message or a unique signal? JAKSTAT 2013. 2: e23060.
94. Bromberg, J. F., Wrzeszczynska, M. H., Devgan, G., Zhao, Y., Pestell, R. G., Albanese, C. and Darnell, J. E., Jr., Stat3 as an oncogene. Cell 1999. 98: 295–303.